Skip to main content

The donors: Shlomit Shteyer and colleagues

The gift: Raising $127,000 and climbing

The cause: Toronto’s Princess Margaret Cancer Centre

Story continues below advertisement

When Shlomit Shteyer joined Toronto-based technology company BlueCat Networks Inc. two years ago, she wanted to know if her colleagues did any charity work.

Ms. Shteyer had been planning to participate in the Ride to Conquer Cancer, a two-day cycling event from Toronto to Niagara Falls, Ont., that raises money for Toronto’s Princess Margaret Cancer Centre. Her brother had been diagnosed with acute myeloid leukemia, a type of blood cancer, and she’d heard about the ride while being tested at Princess Margaret as a possible bone marrow donor. Now, she wondered if anyone at the company would join her in the ride. Her colleagues not only formed a team, they also helped her buy a bike and come up with a training plan.

BlueCat’s 10-member team, captained by Ms. Shteyer, raised $82,000 last year in their first ride. The team is back again this year, with Ms. Shteyer as captain, and they’ll be lining up on Saturday for the start of the 11th annual ride. So far, they’ve raised $45,000.

“It means a lot to me,” Ms. Shteyer said of the support from her colleagues. “It’s very emotional.” Her brother, who lives in Israel, is in remission but Ms. Shyteyer plans to keep raising money for cancer research. “I hope to do the ride again, for sure.”

Report an error Editorial code of conduct
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading…

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.